CIP
CRL icon

Convergence Investment Partners’s Charles River Laboratories CRL Stock Holding History

Convergence Investment Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-23,976
Closed -$1.98M – 339
2016
Q2 		$1.98M Buy
+23,976
New +$1.97M 0.27% 130

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Convergence Investment Partners's CRL Position: Q3 2016 in Review

Convergence Investment Partners sold out of Charles River Laboratories (CRL) in Q3 2016, closing a stake of 23,976 shares — an estimated $1.98M sold.

Convergence Investment Partners first reported a position in CRL in Q2 2016 and held it in 1 quarter. The position peaked at $1.98M in Q2 2016. 284 funds tracked by Wall St. Rank hold CRL as of Q3 2016.

  • Convergence Investment Partners reported no remaining Charles River Laboratories position as of Q3 2016 after selling out during the quarter.
  • Convergence Investment Partners sold 23,976 Charles River Laboratories shares in Q3 2016, an estimated $1.98M.
  • Convergence Investment Partners first reported a position in Charles River Laboratories in Q2 2016 and held it in 1 quarter.
  • Convergence Investment Partners's Charles River Laboratories position peaked at $1.98M in Q2 2016.
  • 284 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2016.

Based on Convergence Investment Partners's 13F filing for Q3 2016, filed 10 Nov 2016.